Skip to content
Jeff Ryckman· @jryckman3 · X·· 12 hours agoScore60
Body

GY020 didn't meet its primary endpoint: 3y success 70% w/ pembro+RT vs 73% RT alone. Leaving study counted as failure. KM RFS numerically favored pembro, but CI crossed 1. G3/4 toxicity 43% vs 15%. RT alone remains my default here. #ESMO26 #radonc https://t.co/tmjNMzulqN https://t.co/KR1rbuVzhW

Heat 0 · 0 likes · 0 replies · 0 reposts

Source: Jeff Ryckman · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org